“The true way goes over a rope which is not stretched at any great height but just above the ground. It seems more designed to make people stumble than to be walked upon.” F.K.

EV+P is a pivotal regimen in la/mUC & 🔜 expanding to MIUC. Proactive AE monitoring, pt 📚, & multidisciplinary collaboration are critical to optimizing safety & efficacy. 🚨 SJS/TEN, DKA, ILD 📋 Baseline & ongoing monitoring for AEs 🔑 Early ID & proactive dose modifications ⬇️

Great memories from #ESMO25! It was a pleasure to discuss with amazing mentors Dr. @Ioanna_Nixon , MPH, PhD, FFMLM, FRCR(hon) and Dr. @DrVilmaPBarcia MD, PhD, MSc . 🌿

First #ESMO ✅ 35k attendees, countless insights and new hopes for patients. Proud to present + receive a Merit Award.Huge thanks to Prof. @DrYukselUrun , Ankara Univ. Oncology, TTOD & my colleagues—mentors and friends @Ioanna_Nixon @DrVilmaPBarcia @myESMO @ESOncology @oncodaily

Day 4 #ESMO25 Highlights: GI: 1. #CM8HW: Ipi/Nivo in MSI mCRC 2. #STELLAR303: Zanza+Atezo in pMMR mCRC 3. #DYNAMICIII: ctDNA in Adj Colon Ca 4. #FORTITUDE101: Bemarituzumab in FGFR2b mG/GEJC GU: 5. #IMvigor011: ctDNA in Adj MIBC 1/10 #OncTwitter @OncoAlert @OncUpdates

1/4 IMVIGOR011 shows ctDNA is a useful predictive and prognostic tool post cystectomy in muscle invasive bladder cancer #ESMO25 . ctDNA positive patients had DFS and OS benifits with atezolizumab. ctDNA negative patients are at a low risk of relapse/cancer death. @OncoAlert

Which combination would you prefer for the first-line treatment in a patient with HER2-positive metastatic bladder cancer? #ESMO25 #bladdercancer @DrYukselUrun @OncBrothers @OncoAlert @tompowles1 @yekeduz_emre @dr_yakupergun

Patient-centered focus with nccRCC SUNNIFORECAST trial presented by #LotharBergmann: 12-mo OS 78.3% (ipi/nivo) vs 68.3% (SOC), p=0.026. CPS>1 → higher ORR/OS with IO; CPS<1 no lift. #ESMO25 #RCC @myESMO @Annals_Oncology @OncLive @OncoAlert

Day 3 #ESMO25 Highlights: Prostate Ca 1. #PSMAddition: LuPSMA in mHSPC 2. #ENZARD: ADT+XRT+/-Enza 3. #EMBARK: Enza biochem recurrent Prostate Ca 4. #CAPItello281: Abi+/-Capi in PTEN Mesothelioma: 5. #DREAM3R: Durva+Chemo 1L #OncTwitter @OncUpdates @OncoAlert 1/11

Which combination would you prefer for the first-line treatment in a patient with HER2-positive metastatic bladder cancer? #ESMO25 #bladdercancer @DrYukselUrun @OncBrothers @OncoAlert @tompowles1 @yekeduz_emre @dr_yakupergun

Lu-177 PSMA has gradually moved from the last line of CRPC treatment to the first. It is now showing activity even in castration-sensitive disease. OS data still need to mature, but Lu-177 is becoming a therapeutic tool for prostate cancer, much like RAI is indispensable for

#ESMO25 general summary👇

🎯 Honored to present two posters at #ESMO25 Berlin! 🇩🇪 🧤 2854P – Neuro Glove: A prospective self-controlled study investigating glove compression as a protective strategy against chemotherapy-induced peripheral neuropathy in women with gynecologic malignancies. 🫁 2865P – LRF

Primary result of Ph3 CAPItello-281 in PTEN-deficient mHSPC #ProstateCancer by @fizazi_karim #ESMO25 👉adding capivasertib + abiraterone to ADT improved rPFS vs abi+ADT (33.2 vs 25.7 mo; HR 0.81, p= 0.034). OS immature; ↑rash & hyperglycemia with Capi @OncoAlert @urotoday

Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science

Fantastic talk by @DrPaulNguyen #ESMO25 👉result of ph3 Enzarad trial👉Addition of ENZA to ADT + radiation did not improve MFS in all high risk localized, the primary endpoint. However, node+ on CT/MRI pts derived benefit, like Stampede trial @OncoAlert @urotoday @PCF_Science

#ESMO25 @petegodolphin presents updated STOPCAP meta-analysis on prostate RT in de novo mHSPC 📊 4 RCTs pooled (HORRAD, STAMPEDE, PEACE-1): 🧍‍♂️ 5–9y FU | 3.2–5.3y median OS 📌 RT + SoC vs SoC alone 🔹 OS: HR 0.92 (95% CI 0.84–1.00; p=0.058) 🔹 PFS: HR 0.88 (95% CI 0.81–0.95;

Reducing our climate footprint? Should we start with ourselves, @myESMO ? In #esmo25 Berlin, ~35,000 participants from 150 countries gather. Two out of every three likely flew here. Average flights return trips included: 3000 km for Europe, at least 12000 km from the US. Just

Day 2 #ESMO25 Highlights: Breast Ca: 1. #DESTINYBreast11 NeoAdj TDXd 2. #DESTINYBreast05: TDXd in residual disease 3. #evERA: Giredestrant HR+ 4. #VIKTORIA1: Gedatolisib HR+ GU: 5. #KEYNOTE905: PeriOp EV + Pembro MIBC @myESMO #OncTwitter @OncoAlert @OncUpdates 1/13

#LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with #mCRPC. Presentation by @SandhuShahneen @PeterMacCC. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/qpP48yqyNi @myESMO @neerajaiims

There is understandable power to 'global' oncology trials, but sponsors need to assure appropriate standards of care are met. In DB-11, > 40% of pts with residual HER2+ BC did not get TDM1, the standard since 2019. It means EFS data are and will be hard to interpret.